Effectiveness and Continuation Rate of Half-dose Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis

Résumé fourni par la source

Objective: To assess the effectiveness and continuation rate of half-dose Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA). Methods: We conducted a retrospective cohort study of 212 patients who initiated JAK inhibitors at our hospital (standard-dose group: 142; half-dose group: 70). Among 141 patients who continued the same dose for more than 6 months (standard-dose: 99; half-dose: 42), propensity score matching was performed based on age, disease duration, sex, number of prior biologics/JAK inhibitors, baseline CRP, CDAI, glucocorticoid dose, methotrexate dose, and mHAQ score. Matched groups (37 per group) were compared for CRP, CDAI, and mHAQ at 6 months and for changes from baseline. Reasons for discontinuation were analysed in 71 patients who discontinued treatment within 6 months. Results: At 6 months, the half-dose group showed significantly higher CRP levels and less improvement in mHAQ scores than the standard-dose group. No significant differences were observed in CDAI or other parameters. Discontinuation due to insufficient effectiveness was significantly more frequent in the half-dose group, whereas discontinuation due to adverse events did not differ between groups. Conclusions: Compared with standard-dose therapy, half-dose JAK inhibitors are associated with reduced effectiveness and higher discontinuation rates owing to insufficient clinical response.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.